A new drug in treating intrahepatic cholangiocarcinoma:FGFR1-4 inhibitor futibatinib
Intrahepatic cholangiocarcinoma(ICC)is a malignant tumor that occurs in the biliary system,with a hidden onset,poor overall prognosis and high mortality.Futibatinib is a fibroblast growth factor receptor(FGFR)1-4 inhibitor,which was approved by the U.S.Food and Drug Administration in 2022 for the treatment of adult patients with previously treated,unresectable,locally advanced or metastatic ICC with FGFR2 gene fusions or other rearrangements.PhaseⅠ and Ⅱ clinical trials have shown that futibatinib has good clinical effect on ICC,which can significantly improve the objective response rate and prolong the survival time of ICC patients.The common adverse events include hyperphosphatemia,diarrhea,constipation,and dry mouth,with a high incidence of adverse events.
NETL
NSTL
万方数据
